Hemostemix disclosed a non-brokered private offering of about 15 million units to shareholders, priced in the context of the market, with each unit consisting of one common share and one common share purchase warrant.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.